Clinical trials: Non Organic Psychosis
Psychosis, Schizophrenia
Cognitive Behavioral Therapy for Patients With an Early Psychosis
The purpose of the present study is to examine whether cognitive behavior therapy will reduce depressive symptoms and increase self-esteem for patients with a first episode psychosis.
- Conditions
- Psychosis, Schizophrenia, Depressive Symptoms, Self-esteem
- Trial name
- NCT01511406
- Testing
- cognitive behavioral therapy
- Where
- Norway
- Volunteers
- 60 people
- Sponsor
- Oslo University Hospital
Disorder; Mental, Sedative, Depressed Level of Consciousness
Use of Bispectral Index Monitoring to Detect Deep Sedation in Mechanically Ventilated Patients: Validity Study
In the previous study, the investigators obtained the cutoff value of Bispectral Index to detect early deep sedation in patients with mechanical ventilation.
- Conditions
- Disorder; Mental, Sedative, Depressed Level of Consciousness, Mechanical Ventilation Complication, Psychosis Associated With Intensive Care
- Trial name
- NCT02439840
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Capital Medical University
Psychotic Disorders
Critical Time Intervention in the Transition From Hospital to Community in People With Severe Mental Illness
This study will evaluate the effectiveness of a psychosocial treatment, Critical Time Intervention, in easing the transition from hospital to community in people with severe mental disorders.
- Trial name
- NCT00621465
- Testing
- Critical Time Intervention (CTI), Usual care
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- New York State Psychiatric Institute
Acute Psychotic Symptoms
Quality Project to Evaluate and Validate the FAST-O Rating Scale
The purpose of this project is to test the reliability of the FAST-O Rating Scale in patients at acute wards or psychiatric intensive care units.
- Trial name
- FAST-O (NCT00913731)
- Where
- 5 sites in Sweden
- Volunteers
- 111 people
- Sponsor
- AstraZeneca
Clinical High Risk for Psychosis, Ultra High Risk for Psychosis
Sacramento Clinical High Risk for Psychosis Stepped-Care Program
This is a dissemination and implementation study that is evaluating a stepped-care intervention for identifying and treating youths at clinical high-risk for psychosis within multiple community mental health centers.
- Trial name
- SCIP Step (NCT06640803)
- Testing
- Stepped-Care including Cognitive Behavioral Case Management
- Where
- 6 sites in United States
- Volunteers
- 223 people
- Sponsor
- University of California, Davis
Alzheimer Disease, Psychosis
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
The purpose of this study is to evaluate KarXT + KarX-EC as a treatment for psychosis associated with Alzheimer's disease.
- Trial name
- NCT06947941
- Testing
- KarXT, KarX-EC
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 325 people
- Sponsor
- Bristol-Myers Squibb
Cannabis Use Disorder, Psychosis
rTMS Treatment for Cannabis Use Disorders in Psychosis
Cannabis use during adolescence represents a significant risk factor for the development of psychosis including schizophrenia. Moreover, cannabis is the most commonly used drug among patients with an existing psychotic disorder.
- Trial name
- NCT03069612
- Testing
- Repetitive Transcranial Magnetic Stimulation (rTMS)
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- Centre for Addiction and Mental Health
Smoking, Nicotine Dependence
Neural Inhibition as a Mechanism of Nicotine Dependence Among Persons With Schizophrenia
Cigarette smoking decreases life expectancy, causes devastating health complications, and costs society billions of dollars each year.
- Conditions
- Smoking, Nicotine Dependence, Schizophrenia, Schizophreniform Disorders
- Trial name
- NCT00407277
- Testing
- Nicotine patch, smoking cessation group therapy
- Where
- Canada
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Psychosis, Substance Use
Brief Motivational Enhancement Therapy for Concurrent Disorders
The investigators are proposing a project that will examine the effectiveness of brief motivational enhancement therapy in a population with concurrent psychotic disorders and substance use disorders.
- Trial name
- NCT01924039
- Testing
- Brief Motivational Enhancement Therapy, treatment as usual
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- Centre for Addiction and Mental Health
Psychotic Disorders, Family Members
Supporting Patients by Family Education in Psychotic Illness: A Prospective Cohort Study
Background: A lack of education, resources, and support for family carers of young adults with psychotic illnesses leaves them ill-equipped to support their loved one.
- Conditions
- Psychotic Disorders, Family Members, Anosognosia, Paranoia
- Trial name
- NCT05500001
- Testing
- Supporting Patients by Family Education in Psychotic Illness Group
- Where
- 4 sites in Canada
- Volunteers
- 113 people
- Sponsor
- University of Alberta
Psychotic Disorders
Optimal Duration of Early Intervention for Psychosis
A total of 160 subjects, who aged 18-35 and had completed the first 2 years of case management in the EASY programme will be randomized in 1:1 ratio into either (1) receiving an additional year of case management, or (2)…
- Trial name
- NCT01202357
- Testing
- Community Case Management
- Where
- China
- Volunteers
- 160 people
- Sponsor
- The University of Hong Kong
Clinical High Risk for Psychosis (CHR), Suicidal Ideation
Developing a Recovery-Oriented Suicide Prevention Program for Young People at Clinical High Risk for Psychosis
Young people at clinical high risk for psychosis are more likely to experience suicide thoughts than the general population, but there are few suicide prevention programs designed specifically for them.
- Conditions
- Clinical High Risk for Psychosis (CHR), Suicidal Ideation, Psychosis, Suicidal Behavior
- Trial name
- NCT07756567
- Testing
- Suicide Prevention Intervention, Standard Care (in control arm)
- Where
- 2 sites in United States
- Volunteers
- 108 people
- Sponsor
- University of California, San Diego
Psychosis
Method of Level (MOL) Therapy for Psychosis
The study is a systematic case replication series of a new psychological therapy Method of Levels (MOL) for people who experience psychosis. Between 6 and 8 people with psychosis who receive services from CMHT will be recruited.
- Trial name
- NCT04038112
- Testing
- psychological therapy Method of Levels (MOL)
- Volunteers
- 6 people
- Sponsor
- University of Manchester
Artificial Intelligence, Septic Shock
Artificial Intelligence for Sepsis Prediction in ICU
The development of sepsis prediction model in line with Chinese population, and extended to clinical, assist clinicians for early identification, early intervention, has a good application prospect.
- Conditions
- Artificial Intelligence, Septic Shock, Intensive Care Unit Psychosis
- Trial name
- AICUSepsis (NCT04913181)
- Testing
- Artificial intelligence sepsis prediction model
- Volunteers
- 2,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Clinical High Risk for Psychosis (CHR)
A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis
The goal of this clinical trial is to learn how tests undertaken by people at high risk of developing psychosis (aged 17 to 30 years old) change when those people are given the study drug MT1988 daily for 8 weeks.
- Trial name
- NCT07226895
- Testing
- MT1988 Low Dose, MT1988 High Dose
- Where
- 15 sites in United States
- Volunteers
- 150 people
- Sponsor
- Monument Therapeutics Limited
Psychosis, Metabolic Syndrome
Evaluating the Effects of Adjunctive Aripiprazole on Weight and Metabolic Outcomes in Females
Patients with psychiatric disorders, including depression, anxiety, and schizophrenia, often require antipsychotic medications for symptom management.
- Conditions
- Psychosis, Metabolic Syndrome, Weight Gain
- Trial name
- NCT06590298
- Testing
- Adjunctive Aripiprazole for improving Weight and Metabolic Outcomes in Females
- Volunteers
- 600 people
- Sponsor
- Universiti Putra Malaysia
Schizophrenia; Psychosis
Evaluating a Novel Mobile App for Social Cognition in Psychosis
To develop, and then evaluate a mobile phone app to deliver therapy homework activities between group sessions (social cognition intervention) in individuals with psychosis.
- Trial name
- NCT04260763
- Testing
- Social Cognition Group, Novel Mobile App
- Where
- United Kingdom
- Volunteers
- 14 people
- Sponsor
- King's College London
Prodromal Schizophrenia
"Multimodal Prevention of Psychosis - Investigating Efficacy of N-Acetylcysteine and Psychotherapy in CHR-Patients"
Schizophrenia is a severe mental disorder associated with significant impairments in affective, cognitive and social functioning.
- Trial name
- ESPRIT-B1 (NCT03149107)
- Testing
- N-Acetylcysteine, IPPI (Integrated Preventive Psychological Intervention), PSM (Psychological stress management)
- Where
- 10 sites in Germany
- Volunteers
- 48 people
- Sponsor
- University Hospital, Bonn
Schizophrenia Spectrum & Other Psychotic Disorders
REFLECT: A Novel Group-Based Compassion-Focussed Cognitive Behavioural Approach to Core Beliefs in Psychosis
The current study is an open-label, proof-of-concept, pilot trial examining the feasibility, safety, and preliminary efficacy of a 6-week group therapy intervention targeting core beliefs related to symptoms of psychosis.
- Trial name
- REFLECT (NCT07569471)
- Testing
- REFLECT: REFlecting on and Learning to Evaluate Core beliefs in real Time
- Where
- Canada
- Volunteers
- 38 people
- Sponsor
- University of Toronto
Schizophrenia, Schizophrenia Relapse
3-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals
This open-label, non-randomized, prospective study will evaluate the risk of symptoms recurrence during the three years after antipsychotic discontinuation in a sample of functionally recovered first-episode patients with…
- Conditions
- Schizophrenia, Schizophrenia Relapse, Schizophrenia Spectrum and Other Psychotic Disorders
- Trial name
- ADARFEP (NCT02220504)
- Testing
- Antipsychotic treatment discontinuation, Maintenance antipsychotic treatment
- Where
- Spain
- Volunteers
- 68 people
- Sponsor
- Fundación Marques de Valdecilla
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.